International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study

The disadvantaged populations eGFR (estimated glomerular filtration rate) epidemiology (DEGREE) study was designed to gain insight into the burden of chronic kidney disease (CKD) of undetermined cause (CKDu) using standard protocols to estimate the general-population prevalence of low eGFR internationally. Therefore, we estimated the age-standardized prevalence of eGFR under 60 ml/min per 1.73m<sup>2</sup> in adults aged 18-60, excluding participants with commonly known causes of CKD; an ACR (albumin/creatinine ratio) over 300 mg/g or equivalent, or self-reported or measured (HT) hypertension or (DM) diabetes mellitus, stratified by sex and location. We included population-representative surveys conducted around the world that were either designed to estimate CKDu burden or were re-analyses of large surveys. There were 60,964 participants from 43 areas across 14 countries, with data collected 2007- 2023. The highest prevalence was seen in rural men in Uddanam, India (14%) and Northwest Nicaragua (14%). Prevalence above 5% was generally only observed in rural men, with exceptions for rural women in Ecuador (6%) and parts of Uddanam (6%‒8%), and for urban men in Leon, Nicaragua (7%). Outside of Central America and South Asia, prevalence was below 2%. Our observations represent the first attempts to estimate the prevalence of eGFR under 60 without commonly known causes of CKD around the world, as an estimate of CKDu burden, and provide a starting point for global monitoring. It is not yet clear what drives the differences, but available evidence supports a high general-population burden of CKDu in multiple areas within Central America and South Asia, although the possibility that unidentified clusters of disease may exist elsewhere cannot be excluded.

Authors

Institutions

Publication Details

Journal
Kidney International
Published
2024-12-19
DOI
https://doi.org/10.1016/j.kint.2024.11.028
Citations
11
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
4.61

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study

Steven Robertson, Marvin González-Quiroz, Dorothea Nitsch, Peter Rohloff et al.
11 citations
Kidney International
Lung Cancer Treatments and Mutations
4.61
article

International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study

Steven Robertson, Marvin González-Quiroz, Dorothea Nitsch, Peter Rohloff, Antonio Bernabé‐Ortiz, Ravi Raju Tatapudi, Dorairaj Prabhakaran, Nalika Gunawardena, Thilanga Ruwanpathirana, Ben Caplin, Sophie Hamilton, Cristina O’Callaghan‐Gordo, Vivekanand Jha, Kristina Jakobsson, Michelle H Hathaway, Jason Glaser, Sandra Cortés, Annibale Biggeri, Neil Pearce, Charlotte E Rutter, Sailesh Mohan, Prabhdeep Kaur, Philip J. Cooper, Sameera Senanayake, Amelia Catharine Crampin, Chagriya Kitiyakara, Anil Poudyal, Meghnath Dhimal, Pubudu Chulasiri, Aurora Aragón, Ajay Singh, Ricardo Correa‐Rotter, Devaki Nair, S. C. Wickramasinghe, Mary Njoroge
article en
11 citations

Abstract

The disadvantaged populations eGFR (estimated glomerular filtration rate) epidemiology (DEGREE) study was designed to gain insight into the burden of chronic kidney disease (CKD) of undetermined cause (CKDu) using standard protocols to estimate the general-population prevalence of low eGFR internationally. Therefore, we estimated the age-standardized prevalence of eGFR under 60 ml/min per 1.73m<sup>2</sup> in adults aged 18-60, excluding participants with commonly known causes of CKD; an ACR (albumin/creatinine ratio) over 300 mg/g or equivalent, or self-reported or measured (HT) hypertension or (DM) diabetes mellitus, stratified by sex and location. We included population-representative surveys conducted around the world that were either designed to estimate CKDu burden or were re-analyses of large surveys. There were 60,964 participants from 43 areas across 14 countries, with data collected 2007- 2023. The highest prevalence was seen in rural men in Uddanam, India (14%) and Northwest Nicaragua (14%). Prevalence above 5% was generally only observed in rural men, with exceptions for rural women in Ecuador (6%) and parts of Uddanam (6%‒8%), and for urban men in Leon, Nicaragua (7%). Outside of Central America and South Asia, prevalence was below 2%. Our observations represent the first attempts to estimate the prevalence of eGFR under 60 without commonly known causes of CKD around the world, as an estimate of CKDu burden, and provide a starting point for global monitoring. It is not yet clear what drives the differences, but available evidence supports a high general-population burden of CKDu in multiple areas within Central America and South Asia, although the possibility that unidentified clusters of disease may exist elsewhere cannot be excluded.

Kidney InternationalVol. 107(3)
University of London (GB), University of Nairobi (KE), Ministry of Public Health (TH), Harvard University (US), University of Padua (IT), Universitat Oberta de Catalunya (ES), University of British Columbia (CA), Johns Hopkins University (US), University of Illinois Urbana-Champaign (US), Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN), Pontificia Universidad Católica de Chile (CL), Manipal Academy of Higher Education (IN), National University of Singapore (SG), The University of Texas at San Antonio Health Science Center (US), Universitat Pompeu Fabra (ES), Utrecht University (NL), Mario Negri Institute for Pharmacological Research (IT), Universidad Peruana Cayetano Heredia (PE), Sri Ramachandra Institute of Higher Education and Research (IN), Mahidol University (TH), University of Michigan (US), Alliance for Clinical Trials in Oncology (US), The Royal Free Hospital (GB), Harvard University Press (US), University of Colorado System (US), Health Net (US), Indian Council of Medical Research (IN), University of Illinois Chicago (US), London School of Hygiene & Tropical Medicine (GB), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), National Institute of Medical Statistics (IN), National Institute of Epidemiology (IN), World Health Organization Regional Office for South-East Asia (IN), Apollo Institute of Medical Sciences & Research (IN), Mayo Clinic Health System (US), Duke-NUS Medical School (SG), Advanced Center for Chronic Diseases (CL), Nepal Health Research Council (NP), Malawi Epidemiology and Intervention Research Unit (MW), George Institute for Global Health (IN), Ramathibodi Hospital (TH), Universidad Internacional del Ecuador (EC), Hospital Universitário da Universidade de São Paulo (BR), Barcelona Institute for Global Health (ES), Ministry of Health, Nutrition and Indigenous Medicine (LK), Instituto Nacional de Cardiología (MX), Medical Research Network (US), Action Network (US), University of Florence (IT), University College London (GB), Imperial College London (GB), Indian Institute of Science Bangalore (IN), University of Chile (CL), Public Health Foundation of India (IN), Uganda Virus Research Institute (UG), Stanford University (US)
National Science Foundation, Eli Lilly and Company, World Health Organization, Styrelsen för Internationellt Utvecklingssamarbete, Harvard University, Johns Hopkins University, London School of Hygiene and Tropical Medicine, Duke-NUS Medical School, Universitat Pompeu Fabra, University College London, European Commission, National University of Singapore, Indian Council of Medical Research, Public Health Foundation of India, Universidad de Chile, Bureau of Policy and Strategy, Ministry of Public Health, Thai Health Promotion Foundation, Universitat Oberta de Catalunya, National Institutes of Health, Johns Hopkins Bloomberg School of Public Health, Medical Research Council, National Science Foundation of Sri Lanka, Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias, H2020 European Research Council
Openalex Percentile: Top 4%
Lung Cancer Treatments and Mutations
4.61
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.